当前位置: X-MOL 学术Adv. Drug Deliver. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Novel antimicrobial agents for combating antibiotic-resistant bacteria
Advanced Drug Delivery Reviews ( IF 16.1 ) Pub Date : 2022-06-04 , DOI: 10.1016/j.addr.2022.114378
Rachel Yoon Kyung Chang 1 , Sue C Nang 2 , Hak-Kim Chan 1 , Jian Li 2
Affiliation  

Antibiotic therapy has become increasingly ineffective against bacterial infections due to the rise of resistance. In particular, ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) have caused life-threatening infections in humans and represent a major global health threat due to a high degree of antibiotic resistance. To respond to this urgent call, novel strategies are urgently needed, such as bacteriophages (or phages), phage-encoded enzymes, immunomodulators and monoclonal antibodies. This review critically analyses these promising antimicrobial therapies for the treatment of multidrug-resistant bacterial infections. Recent advances in these novel therapeutic strategies are discussed, focusing on preclinical and clinical investigations, as well as combinatorial approaches. In this ‘Bad Bugs, No Drugs’ era, novel therapeutic strategies can play a key role in treating deadly infections and help extend the lifetime of antibiotics.



中文翻译:

用于对抗抗生素耐药细菌的新型抗菌剂

由于耐药性的增加,抗生素治疗对细菌感染变得越来越无效。特别是 ESKAPE 病原体(粪肠球菌金黄色葡萄球菌肺炎克雷伯菌鲍曼不动杆菌铜绿假单胞菌肠杆菌种)已在人类中造成危及生命的感染,并且由于高度的抗生素耐药性而成为全球主要的健康威胁。为了响应这一紧急呼吁,迫切需要新的策略,例如噬菌体(或噬菌体)、噬菌体编码的酶、免疫调节剂和单克隆抗体。本综述批判性地分析了这些用于治疗多重耐药细菌感染的有前景的抗菌疗法。讨论了这些新治疗策略的最新进展,重点是临床前和临床研究,以及组合方法。在这个“有病虫害,没有药物”的时代,新的治疗策略可以在治疗致命感染方面发挥关键作用,并有助于延长抗生素的使用寿命。

更新日期:2022-06-04
down
wechat
bug